ACEi reduces hypertension-induced hyperinflammation in COVID-19

Antihypertensive therapy, particularly with the use of an angiotensin-converting enzyme inhibitor, improves outcomes in patients with hypertension and SARS-CoV-2 infection, who are susceptible to hyperinflammation and severe outcomes with COVID-19.